This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tang, R. S.
Right arrow Articles by Haller, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tang, R. S.
Right arrow Articles by Haller, A. A.

 Previous Article  |  Next Article 

Journal of Virology, October 2004, p. 11198-11207, Vol. 78, No. 20
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.20.11198-11207.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Parainfluenza Virus Type 3 Expressing the Native or Soluble Fusion (F) Protein of Respiratory Syncytial Virus (RSV) Confers Protection from RSV Infection in African Green Monkeys

Roderick S. Tang,* Mia MacPhail, Jeanne H. Schickli, Jasmine Kaur, Christopher L. Robinson, Heather A. Lawlor, Jeanne M. Guzzetta, Richard R. Spaete, and Aurelia A. Haller{dagger}

MedImmune Vaccines, Inc., Mountain View, California

Received 29 April 2004/ Accepted 10 June 2004

Respiratory syncytial virus (RSV) causes respiratory disease in young children, the elderly, and immunocompromised individuals, often resulting in hospitalization and/or death. After more than 40 years of research, a Food and Drug Administration-approved vaccine for RSV is still not available. In this study, a chimeric bovine/human (b/h) parainfluenza virus type 3 (PIV3) expressing the human PIV3 (hPIV3) fusion (F) and hemagglutinin-neuraminidase (HN) proteins from an otherwise bovine PIV3 (bPIV3) genome was employed as a vector for RSV antigen expression with the aim of generating novel RSV vaccines. b/h PIV3 vaccine candidates expressing native or soluble RSV F proteins were evaluated for efficacy and immunogenicity in a nonhuman primate model. b/h PIV3 is suited for development of pediatric vaccines since bPIV3 had already been evaluated in clinical studies in 1- and 2-month-old infants and was found to be safe, immunogenic, and nontransmissible in a day care setting (Karron et al., Pediatr. Infect. Dis. J. 15:650-654, 1996; Lee et al., J. Infect. Dis. 184:909-913, 2001). African green monkeys immunized with b/h PIV3 expressing either the native or soluble RSV F protein were protected from challenge with wild-type RSV and produced RSV neutralizing and RSV F-protein specific immunoglobulin G serum antibodies. The PIV3-vectored RSV vaccines evaluated here further underscore the utility of this vector system for developing safe and immunogenic pediatric respiratory virus vaccines.

* Corresponding author. Mailing address: MedImmune Vaccines Inc., 297 N. Bernerdo Ave., Mountain View, CA 94043. Phone: (650) 919-6633. Fax: (650) 919-6611. E-mail: tangr{at}medimmune.com.

{dagger} Present address: GlobeImmune Inc., Aurora, CO 80010.

Journal of Virology, October 2004, p. 11198-11207, Vol. 78, No. 20
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.20.11198-11207.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kohlmann, R., Schwannecke, S., Tippler, B., Ternette, N., Temchura, V. V., Tenbusch, M., Uberla, K., Grunwald, T. (2009). Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus. J. Virol. 83: 12601-12610 [Abstract] [Full Text]  
  • Collarini, E. J., Lee, F. E.-H., Foord, O., Park, M., Sperinde, G., Wu, H., Harriman, W. D., Carroll, S. F., Ellsworth, S. L., Anderson, L. J., Tripp, R. A., Walsh, E. E., Keyt, B. A., Kauvar, L. M. (2009). Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients. J. Immunol. 183: 6338-6345 [Abstract] [Full Text]  
  • Eckardt-Michel, J., Lorek, M., Baxmann, D., Grunwald, T., Keil, G. M., Zimmer, G. (2008). The Fusion Protein of Respiratory Syncytial Virus Triggers p53-Dependent Apoptosis. J. Virol. 82: 3236-3249 [Abstract] [Full Text]  
  • van den Hoogen, B. G., Herfst, S., de Graaf, M., Sprong, L., van Lavieren, R., van Amerongen, G., Yuksel, S., Fouchier, R. A. M., Osterhaus, A. D. M. E., de Swart, R. L. (2007). Experimental infection of macaques with human metapneumovirus induces transient protective immunity. J. Gen. Virol. 88: 1251-1259 [Abstract] [Full Text]  
  • Biacchesi, S., Pham, Q. N., Skiadopoulos, M. H., Murphy, B. R., Collins, P. L., Buchholz, U. J. (2006). Modification of the Trypsin-Dependent Cleavage Activation Site of the Human Metapneumovirus Fusion Protein To Be Trypsin Independent Does Not Increase Replication or Spread in Rodents or Nonhuman Primates.. J. Virol. 80: 5798-5806 [Abstract] [Full Text]  
  • Bukreyev, A., Huang, Z., Yang, L., Elankumaran, S., St. Claire, M., Murphy, B. R., Samal, S. K., Collins, P. L. (2005). Recombinant Newcastle Disease Virus Expressing a Foreign Viral Antigen Is Attenuated and Highly Immunogenic in Primates. J. Virol. 79: 13275-13284 [Abstract] [Full Text]  
  • Schickli, J. H., Kaur, J., Ulbrandt, N., Spaete, R. R., Tang, R. S. (2005). An S101P Substitution in the Putative Cleavage Motif of the Human Metapneumovirus Fusion Protein Is a Major Determinant for Trypsin-Independent Growth in Vero Cells and Does Not Alter Tissue Tropism in Hamsters. J. Virol. 79: 10678-10689 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»